Purespring Therapeutics
- Biotech or pharma, therapeutic R&D
Purespring is a precision nephrology company powered by a technology platform allowing us to create once-and-done therapies for glomerular diseases. We have three programs underway: PS-001 for NPHS2 driven FSGS/SRNS, PS-002 for complement driven glomerular diseases, and PS-003 for an undisclosed target with multi-blockbuster potential. All programs are targeting molecularly defined patient populations. We are on the verge of initiating our first clinical study with PS-002 in IgA nephropathy. Our platform allows us to pursue podocyte targets, while limiting systemic effects. E.g. PS-002 will inhibit complement in glomeruli without affecting the function of systemic complement.
Purespring are looking to meet with potential future partners on our programs at BIO. We are also open to collaborating to pursue novel podocyte targets proposed by a partner.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}